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OBJECTIVES The aim of this study was to determine the effect of angiotensin II type 1 (AT1) receptor
antagonists on pro-oxidant species observed in the pathogenesis of atherosclerosis. Parameters
such as low-density lipoprotein (LDL) susceptibility, monocyte binding capacity, superoxide
generation and lipid peroxidation were examined in the presence of the AT1 receptor
antagonist irbesartan.
BACKGROUND Low-density lipoprotein oxidation is a key component in the process of atherogenesis. This
modification may involve various mechanisms, including changes in nitric oxide levels and
superoxide levels. Additionally, compounds that suppress these mechanisms may retard or
inhibit the pathogenesis of atherosclerosis.
METHODS Forty-seven patients with documented coronary artery disease were treated with irbesartan for
a 12-week period. Patients were randomized to receive irbesartan or placebo. Lipid
peroxidation, superoxide levels, monocyte binding and LDL oxidation were measured at 0, 4
and 12 weeks. Findings were statistically evaluated by two-way repeated measures analysis of
variance with p  0.05 being significant.
RESULTS Treatment with irbesartan significantly decreased the pro-oxidative environment seen in our
study population. Lag time for LDL oxidation increased 32% at 12 weeks, suggesting an
increased resistance of LDL modification in the serum. Thiobarbituric acid reactive
substances activity indicated that lipid peroxidation decreased by 36% in comparison to
placebo. In addition, superoxide levels and monocyte-binding capacity were also significantly
reduced in coronary artery disease patients receiving irbesartan.
CONCLUSIONS Our results indicate that irbesartan may suppress the atherosclerotic process by inhibiting the
intravascular oxidative state and the production of reactive oxygen species, compounds that
may cause damage to the vasculature. (J Am Coll Cardiol 2001;38:1662–7) © 2001 by the
American College of Cardiology
Ongoing research indicates that the abundance of reactive
oxygen species in the vasculature results in an increased
oxidation of proteins including oxidized low-density li-
poprotein (ox-LDL), which initiates an inflammatory pro-
cess and causes intimal damage to the arterial wall (1). The
mechanisms of this damage are not yet established and may
involve the inactivation of nitric oxide (NO) by oxygen-
derived free radicals such as superoxide (2). This inflamma-
tory response affects the gene expression of regulatory
molecules, such as vascular cell adhesion molecule and
tumor necrosis factor-alpha (3–5), which in turn promote
foam cell formation. The reduction in NO levels along with
an increase in ox-LDL may function as immunomodulators
of the atherosclerotic process (6). Recent studies imply that
ox-LDL stimulates an immunological response through the
formation of autoantibodies, resulting in further damage to
the endothelium and acceleration of the atherosclerotic
process (7,8). This antibody response may represent a
marker for the extent of atherosclerosis seen in affected
individuals.
Agents that inhibit the renin-angiotensin system, such as
angiotensin-converting enzyme (ACE) inhibitors and an-
giotensin II type 1 (AT1) receptor blockers, have consider-
able benefit in hypertension and heart failure (9–11).
Studies have shown that AT1 receptor blockers and ACE
inhibitors improve endothelium-dependent vasomotor re-
sponses (12–15). Yet it appears that the AT1 receptor
blockers can produce greater inhibition of effects mediated
by angiotensin II (12). Recently, we have demonstrated that
treatment with AT1 receptor blockers in patients with early
atherosclerosis decreases markers of inflammation that may
be sensitive to the oxidative state in the vasculature (16).
The use of AT1 receptor blockers may be beneficial in
retarding the progression of atherosclerosis because of their
ability to prevent native low-density lipoprotein (LDL)
from being oxidatively modified to ox-LDL (17). It is
possible to speculate that inhibitors of the renin-angiotensin
system such as AT1 receptor blockers may improve endo-
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thelial function by regulation of antioxidant-sensitive mech-
anisms in the vasculature.
In the present study, we wished to determine whether the
regulation of angiotensin II activity via blockade of the
angiotensin II type 1 receptor might affect pro-oxidant
mechanisms critical in the pathogenesis of vascular diseases
such as atherosclerosis.
METHODS
Subjects. Forty-seven subjects (26 men and 21 women), all
with documented coronary atherosclerosis, were enrolled
into the study. All patients had undergone coronary artery
bypass graft and/or percutaneous transluminal coronary
angioplasty at least one year before the start of the study. No
patient had any subjective evidence of acute coronary
syndrome in the year preceding the study. Evidence of
myocardial infarction (MI) was determined by electrocar-
diographic findings, previous history of elevated creatine
kinase-MB isoenzymes, and/or regional wall motion abnor-
mality noted on either ventriculography or echocardiogra-
phy. Left ventricular ejection fraction was determined by
echocardiography. All patients were considered stable on
their medical regimen and free of any acute coronary
syndrome (i.e., MI or unstable angina) for at least 12
months. All subjects were on aspirin, and an equal number
of subjects in each group were on nitrates, beta-blockers and
HMG-CoA reductase inhibitors. No subject had taken
either ACE inhibitors or AT1 receptor inhibitors for at least
six months before the beginning of the study.
A survey was performed on each potential subject, and
the following were excluded: current smokers, patients with
an ejection fraction of 40% by echocardiography or
ventriculography, diabetes with a glycosylated hemoglobin
7.5%, systolic blood pressure (BP) 150 mm Hg, renal
impairment, hepatic impairment or malignancy. The pro-
tocol was approved by the research committee, and all
subjects gave written informed consent.
Study design. Under a randomized, placebo-controlled pro-
tocol, subjects received either irbesartan 150 mg daily (provided
by Bristol-Myers Squibb, Princeton, New Jersey) or placebo
for a 12-week period. Serum samples were collected at 0, 4 and
12 weeks. Clinical characteristics and medications are denoted
in Table 1. All patients tolerated irbesartan or placebo and
completed the 12-week study without difficulty.
Measurement of LDL oxidation in patients with athero-
sclerosis. The plasma was isolated from patients at 0-, 4-
and 12-week intervals, and LDL was isolated via ultracen-
trifugation at 39,000 rpm at 4°C. The LDL was then
oxidized to ox-LDL by an in vitro assay utilizing CuSO4, as
previously described (18). The lag time indicating the
susceptibility of the LDL to oxidize was measured using a
spectrophotometer at 280 nm (18). Values were performed
at least in triplicate.
Monocyte binding to the human CD11b receptor. The
serum of the patients in either the irbesartan or placebo
group was collected at 0, 4 and 12 weeks. Whole-blood
immunotyping was performed in blood samples using
fluorescence-activated cell sorting analysis with a monoclo-
nal antibody to the human CD11b receptor, a protein with
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
AT1  angiotensin II type 1 receptor
BP  blood pressure
CAD  coronary artery disease
13-HPODE  13 hydroperoxy linoleic acid
LDL  low-density lipoprotein
MI  myocardial infarction
NO  nitric oxide
ox-LDL  oxidized low-density lipoprotein
PTCA  percutaneous transluminal coronary
angioplasty
TBARS  thiobarbituric acid reactive substances
Table 1. Patient Demographics and Background Medications
Irbesartan (n  24) Placebo (n  23)
Age, years 62.3  8.9 63.0  7.8
Male/female 13/11 13/10
Hypertension 16 16
Former smoking history 20 19
Diabetes mellitus 10 8
Hyperlipidemia 18 20
Left ventricular ejection fraction (%) 53.6  8.4 52.3  5.9
Previous myocardial infarction 8 6
Starting blood pressure (mm Hg) 136  13 (108–150) 133  12 (111–147)
Starting LDL cholesterol (mg/dl) 126  22 (93–149) 129  19 (100–145)
Background medications
Aspirin 24 (100%) 23 (100%)
Nitrates 8 (33%) 6 (26%)
Beta-blockers 16 (67%) 13 (56%)
Calcium channel blockers 5 (22%) 5 (23%)
HMG-CoA reductase inhibitors 20 (83%) 21 (91%)
Other hypolipidemics 3 (13%) 4 (18%)
LDL  low-density lipoprotein.
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human binding sites and a very high binding affinity to
human monocytes. The monoclonal antibody to the CD11b
receptor was obtained through Pharmingen. The changes in
monocyte CD11b expression were determined with flow
cytometry analysis, as previously described (19).
Superoxide anion generation by neutrophils. A modifi-
cation of the lucigenin-based chemiluminescence assay of
NADPH oxidase activity to measure basal and postactiva-
tion levels of superoxide generation by neutrophils was used
(20,21). Neutrophils were separated from venous blood
using a Ficoll-Hypaque density gradient, and activation of
the neutrophil respiratory burst was achieved using 1 mi-
cromole/l of N-formyl-methionyl-leucyl-phenylalanine
(Sigma Chemical Corp., St. Louis, Missouri). The peak
level of superoxide generated after activation was recorded
in mV/5  105 neutrophils (16,20).
Measurement of lipid peroxidation in plasma. The poly-
unsaturated fatty acid linoleic acid (18:2) is converted into
13-hydroperoxy linoleic acid (13-HPODE) by treatment
with the enzyme lipoxygenase. Previous investigations sug-
gest that 13-HPODE may be involved in the initiating and
propagating steps toward atherosclerosis (22,23). The thio-
barbituric acid reactive substances (TBARS) assay was
performed as an indication of lipid peroxidation in the
plasma by using a colorimetric assay as previously described
(24). One molecule of either malonedialdehyde or
4-hydroxyalkenal reacts with thiobarbituric acid to yield a
stable chromophore (20). Spectrophotometric analysis was
performed at 568 nm.
Statistical analysis. All data are presented as the mean
value  SEM. Comparisons were determined within the
placebo and irbesartan groups (0, 4 and 12 weeks) and
between the placebo and irbesartan groups with two-way
analysis of variance (ANOVA). We determined a p value of
0.05 to be statistically significant. (Bonferroni correction
applied; p values are related to ANOVA).
RESULTS
The clinical characteristics of the study group are noted in
Table 1. The average age of the study population was 62.7
years; 68% of the study population had a previous history of
elevated BP. Patients in the irbesartan group had a starting
BP of 136  13 mm Hg (range 108 to 150 mm Hg) and
those in the placebo group had a starting BP of 133 
12 mm Hg (range 111 to 147 mm Hg). Eighty-three
percent of the study population were former smokers; 38%
of the study population had diabetes mellitus. Eighty
percent of the study population had hyperlipidemia. Start-
ing LDL-cholesterol levels measured at 126  22 mg/dl
(range 93 to 149 mg/dl) and 129  19 mg/dl (range 100 to
145 mg/dl) for the irbesartan and placebo groups, respec-
tively. Thirty percent of the study population suffered from
a previous MI (eight patients in the irbesartan group; six
patients in the placebo group). The average left ventricular
ejection fraction for the irbesartan group was 53.6% versus
52.3% for the placebo group.
All of the patients completed the 12-week course of
either irbesartan or placebo without significant adverse
effect. No significant changes in serum creatinine, blood
urea nitrogen or potassium were noted in either group
before or after treatment. There was an average reduction of
systolic BP by 7  3 mm Hg and diastolic BP by 4 
2 mm Hg in the group of patients treated with irbesartan.
These changes were statistically significant, but no patient
developed hypotension (i.e., systolic BP of 90 mm Hg) at
any time during the study.
Irbesartan affects the susceptibility of LDL to oxidation
in patients with coronary artery disease (CAD). Using
time-course analysis, irbesartan increased the lag time of
LDL oxidation in patients, with a slight increase of 11%
from placebo (Fig. 1) at four weeks of treatment (71.1 
8.3 s vs. 63.1  5.6 s for placebo, NS). Furthermore, there
was an increase of 32% in LDL lag time in the irbesartan
group from placebo at 12 weeks of treatment (93.2 8.4 vs.
62.7  7.6 s, p  0.05). There was no change in serum
cholesterol or LDL cholesterol in any of the patients who
were treated with irbesartan.
Treatment with irbesartan regulates monocyte binding in
the vasculature of patients with stable CAD. Using flow
cytometry analysis, treatment with irbesartan suppressed
monocyte binding to CD11b at four weeks and 12 weeks of
treatment as compared to placebo. Figure 2 indicates that
there was a significant decrease in monocyte binding capac-
ity in the group of patients treated with irbesartan. This
decreased capacity remained constant through the course of
the study. On the other hand, monocyte binding capacity
Figure 1. Irbesartan decreases susceptibility to low-density lipoprotein
(LDL) oxidation in patients with coronary artery disease (CAD). Patients
with CAD were placed on placebo or irbesartan (150 mg/day) for a
12-week period. Serum samples were collected at the start of the study
(0 weeks) and at 4 and 12 weeks of treatment. The LDL was isolated by
centrifugation, and rate of oxidation was measured by spectrophotometric
analysis as described in the Methods section. The p value, as determined by
analysis of variance, was 0.027 for time, 0.0001 for group and 0.014 for
the group-time interaction. Black diamond  placebo; black square 
irbesartan; *p  0.05  difference between 0 weeks and 4 or 12 weeks
within each group; #p  0.05  difference between placebo and irbesartan
groups.
1664 Khan et al. JACC Vol. 38, No. 6, 2001
Irbesartan and the Vascular Oxidative State November 15, 2001:1662–7
continued to increase in the placebo group throughout the
study (from 61% binding at four weeks to 68.9% binding at
12 weeks).
Treatment with irbesartan modifies neutrophil superoxide-
generating capacity in patients with stable CAD. Figure 3
indicates that neutrophil superoxide generating capacity was
markedly reduced in patients treated with irbesartan at both
four and 12 weeks. The figure shows that treatment with
irbesartan reduced neutrophil superoxide-generating capac-
ity by 42% at 12 weeks. In contrast, the placebo group
showed no significant change in neutrophil superoxide-
generating capacity during the 12-week study period.
Irbesartan regulates lipid peroxidation in patients with
CAD. To determine whether lipid-derived free-radical
production is regulated by inhibition of the AT1 receptor,
the TBARS assay was utilized as a measurement of lipid
peroxidation. Patients with stable CAD when treated with
irbesartan showed a reduction in TBARS activity that was
33% and 36% lower than placebo (Fig. 4) at four weeks and
12 weeks (both p  0.05), respectively.
DISCUSSION
The present study assessed the effect of the angiotensin II
type 1 receptor inhibitor irbesartan on oxidative processes
seen in patients with CAD. Our findings demonstrate that
treatment of these patients with irbesartan decreased levels
of lipid peroxidation, monocyte binding and superoxide
production and significantly increased the lag time for the
oxidation of LDL. These findings suggest that irbesartan
possesses certain antioxidant properties in addition to its
ability to lower BP.
Potential antioxidant mechanisms seen with the block-
ade of the angiotensin II type 1 receptor. The binding of
angiotensin II to the AT1 receptor is responsible for most of
the peripheral and central effects of angiotensin II on BP,
osmoregulation and cell growth, and thus for the effect of
the renin-angiotensin system in cardiovascular pathology
(25,26). Drugs that block the renin-angiotensin system have
been shown to provide benefits beyond BP control because
of their inhibition of angiotensin II (27). Recent interest has
focused on the role of angiotensin II acting at the AT1
Figure 2. Irbesartan decreases monocyte binding the CD11b monoclonal
antibody in patients with coronary artery disease (CAD). Patients with
CAD were placed on placebo or irbesartan (150 mg/day) for a 12-week
period. Serum samples were collected and red blood cells were lysed. Using
flow cytometry analysis, whole-blood monocyte CD11b expression was
performed. The values expressed are a percentage of expression of CD11b
by circulating monocytes. The p value, as determined by analysis of
variance, was 0.0001 for time, for group and for the group-time
interaction. Black square  placebo; white square  irbesartan; *p 
0.05  difference between 0 weeks and 4 or 12 weeks within each group;
#p  0.05  difference between placebo and irbesartan groups.
Figure 3. Irbesartan decreases production of superoxide in the neutrophils
of patients with coronary artery disease. Serum samples were collected from
the patients who were placed on placebo or irbesartan (150 mg/day) for a
12-week period. Samples were collected at the start of the study (0 weeks)
and at 4 and 12 weeks of treatment. The neutrophils were isolated and the
peak levels of superoxide production after neutrophil respiratory burst were
performed. The p value was 0.0001, as determined by analysis of
variance, for time, for group and for the group-time interaction. Black
diamond  placebo; black square  irbesartan; *p  0.05  difference
between 0 and 4 or 12 weeks within each group; #p  0.05  difference
between placebo and irbesartan groups.
Figure 4. Irbesartan decreases lipid peroxidation in the serum of patients
with coronary artery disease. Serum samples were collected during the
12-week period of treatment at the start of the study (0 weeks) and at 4 and
12 weeks of treatment. The thiobarbituric acid reactive substances
(TBARS) assay was performed, as described in the Methods section, using
spectrophotometric analysis at 568 nm. The p value, as determined by
analysis of variance, was 0.027 for time, 0.012 for the group and 0.004 for
the group-time interaction. Black square  placebo; white square 
irbesartan; *p  0.05  difference between 0 weeks and 4 or 12 weeks
within each group; #p  0.05  difference between placebo and irbesartan
groups.
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receptor in the vasculature, specifically in the processes of
atherosclerosis (26).
In the current study, we determined that irbesartan
reduces the susceptibility of LDL to oxidize in patients with
CAD. These patients had LDL cholesterol values that were
treated with lipid-lowering agents, and treatment with
irbesartan did not alter their LDL cholesterol values during
the entire course of the study. It has been reported previ-
ously that saralasin, an AT1 receptor blocker, inhibits
angiotensin II macrophage-mediated oxidation of LDL
(17). Additionally, our findings indicate that treatment with
irbesartan reduces the adhesion of monocytes in whole
blood. Therefore, it may be that cells such as monocytes are
inactivated in their ability to induce mechanisms of inflam-
mation that are significant in atherogenesis.
The study also showed that treatment of CAD patients
with irbesartan reduced the capacity of neutrophils to make
superoxide anion. The NAD(P)H oxidase system in endo-
thelial cells, smooth muscle cells and phagocytes is an
important source of reactive oxygen species in cardiovascular
disease (20,28), and this activity may be regulated by
angiotensin II operating primarily through the AT1 recep-
tor. It has been shown that angiotensin II mediates vascular
superoxide production via the NAD(P)H oxidase system
(29,30) and that cardiovascular diseases exhibit increased
levels of superoxide in the vasculature (16,20,31). Our
findings suggest that inhibition of the AT1 receptor regu-
lates the production of reactive oxygen species that may in
turn modulate the oxidative state in the vasculature. These
findings suggest that the reduction of reactive oxygen
species such as superoxide anion by irbesartan may be
significant in decreasing irbesartan’s ability to modify LDL
to an oxidized form. This decrease in turn may reduce the
uptake of LDL by inflammatory cells via the scavenger
receptor or other receptors that would subsequently form an
atherogenic foam cell seen in the pathogenesis of athero-
sclerosis. Furthermore, these inhibitory mechanisms would
then reduce the ability of inflammatory cells such as mono-
cytes to adhere to the vessel wall and thereby reduce the
formation of an atherosclerotic plaque. These potential
antioxidant mechanisms may be specific to irbesartan and its
chemical structure and may not necessarily be an effect of
this class of antihypertensive compounds.
Our findings with the TBARS assay indicate that irbe-
sartan reduced the oxidative stress responsible for lipid
peroxidation. It has been observed that oxidative stress may
contribute to endothelial dysfunction in cardiovascular dis-
eases such as atherosclerosis by reducing NO synthase
activity and by reacting with NO to form peroxynitrite
(20,32). Recent studies in the aorta suggest that angiotensin
II interacts with the bradykinin/NO system by an AT2
receptor-dependent mechanism (33,34). Recent studies in-
dicate that the AT2 receptor mediates antiproliferative and
potentially antioxidative effects (35–37), and it is conceiv-
able that many if not all of the antioxidant effects by
irbesartan may be modulated by upregulation of AT2
receptor activity. Further investigations must be undertaken
to assess the validity of these potential mechanisms of
action.
Study limitations. Our findings are primarily confined to
patients with known CAD, and it is not clear whether
treatment with irbesartan would be beneficial in the primary
prevention of CAD. Unlike AT1 receptor inhibitors such as
losartan or valsartan, the pharmacological properties of
irbesartan are that the compound blocks 100% of the AT1
receptor and has insurmountable properties (38). This
difference indicates that the properties seen with irbesartan
should not be considered a class effect of the AT1 receptor
antagonists and that further investigations with the other
AT1 receptor inhibitors need to be performed. Also, the
TBARS assay is not an accurate indicator of the oxidative
state in the vasculature, but it is an indirect measurement of
lipid peroxidation, and has been utilized with reliable results
in previous investigations (20,24). Finally, our results have
been observed in only 12 weeks of therapy. A large group
study of long-term therapy with an AT1 receptor inhibitor,
similar to previous reported results with ACE inhibitors
(39), is required to determine whether these agents would
be beneficial in secondary prevention of CAD.
Conclusions. Because inflammatory and pro-oxidant
mechanisms are significant in the pathogenesis of athero-
sclerosis, the findings in the present study suggest that AT1
receptor inhibitors such as irbesartan may have benefits in
treatment of atherosclerosis. We have previously shown that
irbesartan reduces markers of inflammation in the serum of
patients with early CAD (16). The present findings extend
these observations to indicate that antioxidant-sensitive
mechanisms may be responsible for reducing these inflam-
matory markers independent of BP reduction.
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